AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

Trial details

Who runs it

Shape Memory Medical, Inc.

Trial code

NCT06029660

Record updated

10 July 2026

Original description

To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.Read full original descriptionShow less

To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.

Inclusion: ≥18 years of age; A candidate for elective EVAR of an infrarenal fusiform aortic aneurysm ≥5.5 cm in diameter in men and ≥5.0 cm in women; Thrombus burden (percentage of the AAA sac occupied by thrombus) <50%, based on pre-procedure CTA; Maximum Lumen diameter within the AAA sac of ≥40mm; The predicted minimum number of IMPEDE-FX RapidFill Implants for the subject is ≤200.

Exclusion: Concomitant iliac artery ectasia or aneurysm; Vascular disease and/or anatomy that preclude the safe access and positioning of a catheter to deliver the investigational product into the AAA sac; Use of embolic devices other than the investigational product to embolize the AAA sac; Cerebrovascular accident within 3 months prior to the procedure; Myocardial infarction and/or major heart surgery within 3 months prior to the procedure; Pregnant or lactating female: for females of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the trial; Ruptured, leaking, inflammatory or mycotic (infected) aneurysm; Connective tissue disorder (e.g., Marfan's syndrome); Aneurysmal disease of the descending thoracic aorta; Inability to land the distal-most portion of the EVAR stent graft limbs, including extensions, above the internal iliac arteries; Medical History/Conditions; Coagulopathy or uncontrolled bleeding disorder; Known hypersensitivity or contraindication to platinum, iridium, or polyurethane; A condition that inhibits radiographic visualization during the implantation procedure; History of allergy to contrast medium that cannot be managed medically, or subject is unable to have a CT with contrast for any reason; Uncontrolled co-morbid medical condition, including mental health issues, that would adversely affect participation in the trial; Serum creatinine level >2.5 mg/dL; Have active infection at the time of the index procedure documented by pain, fever, drainage, positive culture, or leukocytosis (WBC >11,000/mm3); Life expectancy of <2 years post-procedure; General; An inability to provide informed consent; Enrolled in another clinical study that could interfere with the outcomes being studied in this trial; Unable or unwilling to comply with study follow-up requirements; Prisoner or member of other vulnerable population; Anatomical; Excessive calcification at the aortic bifurcation to common/internal iliac bifurcation, that might lead to access difficulties; EVAR/Procedural; Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis, Gore Excluder Conformable AAA Endoprosthesis, Cook Zenith Flex AAA Endovascular Graft, Medtronic Endurant II and Endurant IIs Stent Graft, or the Terumo TREO Stent Graft to treat the AAA; Use of an aortic stent graft other than those specified1 for a particular site; Planned use of the chosen stent graft outside its instructions for use (IFU); Use of fenestrated stent grafts or chimney techniques; Use of the Heli-FX EndoAnchor system; Use of embolic products to prophylactically or concomitantly embolize the inferior mesenteric artery, lumbar arteries, renal accessory arteries, or internal iliac arteries; Atrial fibrillation that is not well rate controlled.

ClinicalTrials.gov NCT06029660